MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment

(2018) Voon Yee-Lin et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Which neoadjuvant chemotherapy regimen should be recommended for patients with advanced nasopharyngeal carcinoma?

(2018) Cheng Yuan et al.   MEDICINE

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

(2017) Veronica Tisato et al.   Journal of Hematology & Oncology

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

(2017) Maryam Zanjirband et al.   Oncotarget

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer

(2016) Maryam Zanjirband et al.   Oncotarget

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

(2014) B. Higgins et al.   CLINICAL CANCER RESEARCH

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma

(2012) Jeffrey Kit Loong Tuan et al.   RADIOTHERAPY AND ONCOLOGY

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial

(2011) Nancy Y Lee et al.   LANCET ONCOLOGY

Treatment approaches to nasopharyngeal carcinoma: a review

(2010) Francesco Caponigro et al.   ANTI-CANCER DRUGS

Translating p53 into the clinic

(2010) Chit Fang Cheok et al.   Nature Reviews Clinical Oncology